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Parenteral artesunate has been shown to be a superior treatment option compared to parenteral quinine in adults
and children with severe malaria. Little evidence, however, is available on long-term safety. Recently, cases of
late-onset haemolysis after parenteral treatment with artesunate have been reported in European travellers with
imported Plasmodium falciparum malaria. Therefore, an extended follow-up of adult patients treated for severe
imported malaria was started in August 2011 at the University Medical Center Hamburg-Eppendorf. Until January
2012, three patients with hyperparasitaemia (range: 14-21%) were included for analysis. In all three patients, delayed
haemolysis was detected in the second week after the first dose of intravenous artesunate. Reticulocyte production
index remained inadequately low in the 7 – 14 days following the first dose of artesunate despite rapid parasite
clearance. Post-treatment haemolysis after parenteral artesunate may be of clinical relevance in particular in
imported severe malaria characterized by high parasite levels. Extended follow-up of at least 30 days including
controls of haematological parameters after artesunate treatment seems to be indicated. Further investigations are
needed to assess frequency and pathophysiological background of this complication.
Keywords: Severe imported malaria, Artesunate, Haemolysis, ReticulocytesBackground
Approximately 10,000 to 12,000 malaria cases imported
to Europe are reported to the World Health
Organization (WHO) annually [1]. In Germany, 617
cases of imported malaria were reported to the Robert
Koch Institute in 2010, with an overall mortality rate of
0.3% (two cases) [2]. In a recent retrospective French
study on patients with severe imported malaria – 97.8%
of which were treated with intravenous quinine - mortality
was determined to be 10.5% [3].
Parenteral artesunate has been shown to be a superior
treatment option compared to parenteral quinine in
adults and children with severe malaria in endemic
countries [4,5]. In a large meta-analysis a significant re-
duction in mortality could be confirmed for adults* Correspondence: t.rolling@uke.de
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reproduction in any medium, provided the or(relative risk (RR) 0.61) and children (RR 0.76) treated
with parenteral artesunate compared to parenteral quin-
ine [6]. Artesunate showed a superior parasite clearance
time compared to quinine. Artesunate is now the first-
line treatment for severe malaria according to WHO
guidelines [7].
Regarding short-term safety, hypoglycaemia occurred
significantly less frequently in patients treated with arte-
sunate. In children but not in adults, however, the inci-
dence of neurological sequelae at the time of discharge
was higher after treatment with artesunate compared to
quinine which might be due to the fact that more se-
verely diseased children survived. There was no differ-
ence discernible on long-term neurologic sequelae
between artesunate and quinine arms 28 days after dis-
charge in the African multicentre trial by Dondorp et al.
[5,6]. Little evidence is available in particular on long-
term safety due to trial designs and/or lacking infrastruc-
ture in endemic regions [8]. Very recently, cases of late-
onset haemolysis have been reported retrospectively inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The aetiology of this complication is unknown.
An extensive follow-up of patients treated for severe
malaria to detect any uncommon findings and complica-
tions after parenteral artesunate was implemented at the
University Medical Centre Hamburg-Eppendorf. From
the beginning of this follow-up programme in August
2011 to January 2012, three patients with hyperparasi-
taemia were treated with parenteral artesunate, all of
which developed late-onset haemolysis.
Case presentation
Patient 1
The first patient was a 19-year old German female with-
out migrational background presenting without any co-
morbidities or prior medication who stayed in Uganda
for three weeks. She did not take any malaria prophy-
laxis. Four days after returning to Germany she devel-
oped fever and headaches. At the emergency department
of a community hospital, she was diagnosed with un-
complicated malaria and showed 2% parasitaemia. She
was transferred to a tertiary care centre specializing in
tropical medicine for treatment of uncomplicated mal-
aria. At the first evaluation in the emergency department
(day 0), she did not fulfill any of the WHO criteria for
severe malaria [7], and in line with the guidelines by the
German Society of Tropical Medicine and International
Health (DTG) treatment with mefloquine was initiated
(starting with 750 mg) [10]. Over the next three to four
hours, the patient’s clinical condition deteriorated. She
became somnolent and her blood pressure dropped to
80/50 mmHg with a pulse rate of 108 bpm. At this time
point, Giemsa-stained blood microscopy revealed a para-
sitaemia of 14%. The patient was now classified as com-
plicated life-threatening malaria and was transferred to
the intensive care unit. Intravenous artesunate (Guilin
pharmaceutical factory, China) was given in four doses
of 120 mg on day 0 and after 12, 24 and 48 hours
equivalent to a total dose of 8mg/kg body weight. Be-
cause of thrombocytopenia of 15,000/μl (normal range:
150,000-400,000), she received one unit of packed
thrombocytes. Indirect Coombs’ test was negative at this
time. On day 1, her clinical condition improved strik-
ingly and she was transferred to a regular ward on day 2.
Anti-malarial treatment was continued orally with mef-
loquine (500 mg on day 2 followed by 250 mg eight
hours later, equivalent to a total dose of 1500 mg includ-
ing the initial dose of 750 mg on day 0). Parasitaemia
declined rapidly from initially 14% to 10% after 12h and
finally to less than 1% on day 3. On day 5, parasites were
cleared. Two days later, the patient developed fever again
and showed radiological signs of lung infiltration.
Piperacillin-Sulbactam was started for hospital acquired
pneumonia for 7 days. Hb dropped from 12 mg/dl(normal range: 12.3 - 15.3) at presentation to 10.2 mg/dl
on day 2, stabilized between days 2 and 4 and decreased
again in the following days to 8.6 g/dl on day 14. The
decrease in Hb was accompanied by a second rise in lac-
tate dehydrogenase (LDH) to 1010 U/l indicative of
haemolytic anaemia (Figure 1A and 1B). Blood micros-
copy remained negative at this time point. Because of a
slow but continuous clinical improvement she was dis-
charged from hospital but follow-up was continued at
the tropical medicine outpatient clinic. On day 16, the
lowest Hb was measured but was accompanied with a
significant rise in reticulocytes. Hb increased further
during the following two weeks up to 11.2 g/dl (normal
range: 12.3 - 15.3) on day 30 when the patient was with-
out further clinical complaints.
Patient 2
The second patient was a 54-year old German male
without migrational background returning from a one
week-trip to Gambia. No malaria prophylaxis was taken.
Prior medical history included surgically resected colo-
rectal carcinoma two years earlier and arterial hyperten-
sion. His current medication consisted of metoprolol,
hydrochlothiazide and felodipine for hypertension. Eight
days after returning to Germany, he developed fever up
to 41°C. The primary care physician diagnosed commu-
nity acquired pneumonia and prescribed doxycycline for
7 days. After completing this course of antibiotic treat-
ment, the symptoms still persisted and the patient be-
came icteric. He presented himself to the emergency
ward of a community hospital. Malaria was diagnosed
and the patient was referred to a tertiary care hospital
specializing in tropical medicine. Upon presentation at
the tertiary care hospital (day 0), he appeared somnolent
and showed hypotension of 100/50 mmHg with a pulse
rate of 120 bpm. Hyperparasitaemia of 21% was diag-
nosed in Giemsa-stained microscopy. Furthermore,
hyperbilirubinaemia (total bilirubin: 7.4 mg/dl, normal
range: <1.2) and acute renal failure (creatinine: 3.4 mg/
dl, normal range: 0.6 - 1.3; urea: 91 mg/dl, normal range:
8–26) were present. He was transferred to the intensive
care unit and intravenous artesunate (Guilin Pharma-
ceutical Factory, China) was given in a total of four
doses of 160 mg on day 0, after 12, 24 and 48 hours
equivalent to a total dose of 9 mg/kg body weight. For
haemodynamic support, he had to receive norepineph-
rine intermittently. On day 1, he received one unit of
packed thrombocytes for thrombocytopenia of 7,000/μl
(normal range: 150,000 - 400,000). Two units of packed
red blood cells were transfused for anaemia at an Hb of
7.7 g/dl (normal range: 14.0 - 17.5) on day 3. Anti-
malarial treatment was continued with oral atovaquone/
proguanil on day 3 (three doses of 1000 mg atovaquone
and 250 mg proguanil each) and on day 5 the patient
Figure 1 Time course of haemoglobin (Hb) levels / reticulocyte production index (RPI) as well as lactate dehydrogenase (LDH) levels in
patient 1 (A and B), patient 2 (C and D, arrows indicating time points of transfusions) and patient 3 (E and F).
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declined rapidly from 21% initially to 12% on day 1 and
1.5% on day 3. On day 7, blood film was negative. Two
weeks after initial presentation at the tertiary care hos-
pital, the Hb reached its lowest level of 5.7 g/dl (normal
range: 14.0 - 17.5) with a concurrent rise in LDH, which
peaked on day 21 (Figure 1C and D). Haptoglobin could
not be detected consistent with haemolytic anaemia. No
malaria parasites could be detected at this time point.
The patient received an additional two units of packed
red blood cells each on day 14 and on day 21. The pa-
tient was discharged on day 25. During follow-up,
haemoglobin increased to 11.6 g/dl (normal range: 14.0 -
17.5) on day 49 while LDH decreased and the patient
recovered clinically. This patient showed irregularities in
the immune-haematological testing. On day 2, theindirect Coombs’ test was negative. On day 18, the indir-
ect Coombs’ test was inconclusive while the direct
Coombs’ test was positive for IgG specificity. On day 22,
both indirect and direct Coombs test were negative
again. On a repeated testing on day 23, indirect Coombs’
test was inconclusive and direct Coombs’ test was posi-
tive. The screening for complement factor C3d was
negative. The specificity of the IgG antibodies could be
shown to be anti-E with a very low titer of 1:1. The
patient’s erythrocytes’ phenotype was A Rh pos CCD.ee
Kell neg, none of the transfused units of packed red
blood cells had Rh E phenotype.
Patient 3
The third patient was a 55-year old German male (no
migrational background) without any co-morbidities or
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Senegal and Gambia where he stayed for one week with-
out malaria prophylaxis. Ten days after returning to
Germany he developed multiple fever episodes up to
39°C and chills without any other complaints. He pre-
sented to a community hospital emergency department
where the following laboratory findings were obtained:
creatinine 3.6 mg/dl (normal range: 0.6 - 1.3), urea 43
mg/dl (normal range: 8–26) and total bilirubin 7.1 mg/dl
(normal range: <1.2). Giemsa-stained microscopy
revealed a parasitaemia of 20% and the patient was
transferred to a tertiary care hospital specializing in
tropical medicine for treatment of severe malaria. Sur-
prisingly, the patient did not present any clinical com-
plaints or symptoms upon first evaluation in the tertiary
care hospital (day 0). Because of the laboratory diagnosis
of severe malaria (hyperparasitaemia), a course of intra-
venous artesunate was provided in four doses of 240 mg
on day 0, after 12, 24 and 48 hours, equivalent to a total
dose of 9 mg/kg body weight which was switched to oral
atovaquone/proguanil on day 3 (three doses of 1000 mg
atovaquone and 250 mg proguanil each). Parasite levels
declined rapidly from 20% initially to less than 1% on
day 3. On day 9, the patient was discharged on his own
explicit wish in good health condition. The patient’s ini-
tial Hb of 14.7 mg/dl decreased rapidly during the first
day of hospitalization and was stabilized at 10.7 g/dl at
discharge (normal range: 14.0 - 17.5) mg/dl; Figure 1 E).
On the scheduled follow-up visit on day 13 in the tropical
medicine clinic, a decrease in haemoglobin to 8.2 g/dl as
well as a rise in LDH was detected and the patient was
hospitalized again for further evaluation. Haemolysis was
confirmed, haptoglobin was absent. The lowest haemo-
globin was measured on day 15 with a value of 6.6 g/dl
(normal range: 14.0 - 17.5), LDH peaked on day 17
(Figure 1E and 1F). Immune-haematological testing was
performed on days 14 and 18. Direct and indirect
Coombs’ tests were negative. No blood transfusions were
given and the patient left the hospital against our strong
advice on day 19. In the follow-up visits at his primary
care physician, Hb levels were rising and LDH declined
further while the patient’s clinical condition recovered
fully (Figure 1E and 1F).
Discussion
This case series describes three cases of late-onset haem-
olysis after parenteral artesunate for severe malaria in
non-immune travellers returning from sub-Saharan
Africa. In all three patients, an initial stabilization of Hb-
and a decline of elevated LDH-levels in the first week
after treatment initiation was seen. In the second week,
Hb levels continued to decline while around day 14 a
second rise in LDH levels was observed. At this time
point haptoglobin was undetectable and total bilirubinrose again. Re-occurrence of biochemical markers com-
patible with delayed haemolytic anaemia 1–2 weeks after
starting parenteral artesunate contrasted the rapid clin-
ical improvement seen early after administering the first
dose. Blood stage parasites were cleared around day 4–5
and all patients remained parasite-free during follow-up.
One patient required blood transfusions. In all cases,
haemolysis resolved slowly and Hb levels had not
returned to normal levels 30 days after treatment
initiation.
These findings are in line with a recent report by Zoller
et al. [9]. Of 25 patients in seven centres for whom data
were available, six developed a self-limiting episode of
haemolytic anaemia, which was passively detected be-
tween days 15 and 32 (median: 15.5). Five of the patients
required blood transfusions, all patients recovered fully.
As this case report is only descriptive and no control
group (e.g. treated with quinine) exists, it is not possible
to state with absolute certainty that the observed haem-
olysis is drug-related rather than disease-specific. The
literature on longer-term follow-up of haematological
parameters after severe malaria in general as well as in
relation to specific antimalarial treatment is scarce. One
report of 192 children treated with quinine showed a
(clinically nonsignificant) drop in Hb after treatment and
stabilization between days five and 21 [11]. The lack of a
standardized follow-up precludes any definite statement
on post-treatment haemolysis from this report. In dec-
ades of intensive use of quinine, no reports of post-
treatment haemolysis have been published, which ren-
ders the existence of a comparable complication after
quinine unlikely but not impossible.
Haemolytic anaemia is a characteristic finding in acute
malaria. The aetiology of malarial anaemia is multifactorial
and includes destruction of infected and uninfected
erythrocytes as well as impaired erythropoiesis. Both, para-
site toxicity as well as host immune mechanisms are caus-
ally involved [12]. Impaired erythropoiesis is reflected by a
low reticulocyte production index (RPI) – which was also
seen initially in the three patients described in this series
(Figure 1). Usually, however, RPI rises concurrently with
parasite clearance [13,14]. An adequate rise in RPI was
delayed until the second week – long after parasites had
been cleared and approximately at the time when haemo-
lytic anaemia was diagnosed (Figure 1). Artemisinins have
been reported to target erythropoiesis and to reduce
reticulocyte counts several days after treatment [15,16]
possibly explaining the late rise of RPI. Additionally, in the
first patient the development of pneumonia could
have prolonged inflammation-mediated impairment of
erythropoiesis. No secondary infection can however ex-
plain the finding in the other two patients.
An explanation of a second peak of haemolysis might
lie in the reduced life span of “pitted” erythrocytes. The
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cantly after treatment with artesunate but not with
quinine [17,18]. This mechanism would explain the cor-
relation between delayed haemolysis and hyperparasitae-
mia, as the number of “pitted” erythrocytes is related to
parasitaemia. This is supported by the facts, that i) all
three patients had parasite levels of >10% infected red
blood cells and that ii) all cases with post-treatment
haemolysis described by Zoller et al. also had high para-
site levels upon presentation (4 - 30%) [9].
Another potential explanation of late-onset haemolysis
includes a delayed (re-)activation of pro-inflammatory
reactions possibly triggered by the rapid and massive de-
struction of malaria parasite by artesunate and an
increased presentation of parasitic antigens.
The fact that the patients described in this report
received lower cumulative doses of artesunate than those
in the publication by Zoller et al. [9] argues against a
dose-dependent effect.
One (patient 2) of the two patients receiving immuno-
haematological testing developed a positive Coombs’ test
with IgG of anti-E specificity. This patient was the only
one to receive packed red blood cell transfusions repeat-
edly after the first dose of artesunate. A delayed haemo-
lytic transfusion reaction cannot be completely excluded
in this patient, although it seems very unlikely. Delayed
haemolytic transfusion reactions generally occur follow-
ing alloimmunization after a previous transfusion. The
time of onset is usually two to eleven days after the
transfusion. The extent of haemolysis is mostly mild
without clinical implications as only the transfused ery-
throcytes are being destroyed [19,20]. The titer of the
detected antibody in our patient was extremely low and
would not explain the amount of haemolysis seen in this
patient. More important seems to be the fact that this
patient showed the most severe malaria symptoms as
well as the highest parasitaemia upon hospitalization
(21%). In the case series by Zoller et al., Coombs’ test
was negative in all three patients in whom this test was
performed [9]. All in all, this does not rule out immune-
mediated haemolytic anaemia, but this has to be investi-
gated in greater detail.
Two of the patients received drugs with anti-
malarial activity prior to the first dose of artesunate.
Patient 1 received 750 mg of mefloquine while pa-
tient 2 received a seven-day course of doxycycline for
suspected bacterial infection. It is unclear whether
these medications may have contributed to delayed
haemolysis.
Conclusions
After treating three hyperparasitaemic patients with par-
enteral artesunate, malaria parasites were cleared within
a few days and the patients’ clinical condition improvedrapidly. Post-treatment haemolysis, however, seems to be
a relevant complication in non-immune travellers with
imported malaria. Risk factors and pathophysiology are
unknown. To gain statistically significant results for
patients with imported severe malaria, data from cases
at multiple centres will have to be accumulated in a
standardized manner. Whether this complication also
occurs in children with severe malaria in endemic
regions is currently unknown. A regular follow-up of at
least one month after treatment with parenteral artesu-
nate including controls of haematological parameters
seems to be indicated.
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